Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Citrine Approved to Launch Rare Disease Drug in China without Clinical Trial

publication date: Mar 22, 2021

Citrine Medicine, a Shanghai-Boston rare disease company, received a waiver to market a treatment for narcolepsy in China without a clinical trial. Six months ago, Citrine acquired China rights to Wakix® (pitolisant), a drug already approved in the EU and US to treat narcolepsy in adult patients with and without cataplexy. Citrine will file an NDA in China using data from the US and Europe. Citrine's $80 million Series A round was led by Quan Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital